Monte Rosa Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $611.00K, a 67.40% increase year-over-year.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $365.00K, a 22.48% increase year-over-year.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $298.00K, a 1.65% decline year-over-year.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $303.00K.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $735.00K, a 39.47% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $527.00K, a 8.82% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $578.00K, a 72.02% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $336.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $611.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $735.00K 10-K · filed 2026-03-17 | |
| 2025-06-30 | $365.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $527.00K 10-K · filed 2026-03-17 | |
| 2024-06-30 | $298.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $578.00K 10-K · filed 2025-03-20 | |
| 2023-06-30 | $303.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $336.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $13.21M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |